Systemic Anaplastic Large Cell Lymphoma News and Research

RSS

Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Systemic ALCL is a type of T-cell non-Hodgkin lymphoma that expresses the CD30 antigen. Although standard front-line combination chemotherapy regimens used to treat systemic ALCL often result in long-term remissions and cures, there are limited therapeutic options and a strong unmet medical need for patients with relapsed or refractory disease. SGN-35 has received orphan drug designation for ALCL from both the FDA and the European Medicines Agency.

FDA accepts SGEN's brentuximab vedotin BLAs for Hodgkin lymphoma, ALCL treatment

Seattle Genetics, Inc. announced today that the U.S. Food and Drug Administration has accepted for filing two Biologics License Applications for brentuximab vedotin, including one for the treatment of patients with relapsed or refractory Hodgkin lymphoma and one for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma.

2 May 2011

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics, Inc. today announced that data from a case series of Hodgkin lymphoma patients receiving brentuximab vedotin following allogeneic stem cell transplant were presented in an oral session at the European Group for Blood and Marrow Transplantation Annual Meeting in Paris, France.

7 Apr 2011

SGEN, Abbott enter collaboration agreement for ADC products

Seattle Genetics, Inc.today announced that it has entered into a collaboration agreement with Abbott under which Abbott will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single oncology target.

23 Mar 2011

Millennium, SGEN expand ADC collaboration

Seattle Genetics, Inc. announced today that Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, has paid an undisclosed fee to exercise an option to designate a second antigen target under the parties' existing antibody-drug conjugate (ADC) collaboration.

16 Mar 2011

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin in combination with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma patients.

1 Mar 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

Seattle Genetics enters ADC collaboration agreement with Pfizer

Seattle Genetics, announced today that it has entered into a collaboration agreement with Pfizer under which Pfizer will pay an upfront fee of $8 million for rights to utilize Seattle Genetics' antibody-drug conjugate technology with antibodies to a single oncology target.

7 Jan 2011

$Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL$

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive data from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, a defining marker of ALCL. The data were presented today during an oral session at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL.

7 Dec 2010

$Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010$

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive results from the pivotal trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate targeted to CD30, a defining marker of Hodgkin lymphoma.

6 Dec 2010

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited today announced that brentuximab vedotin (SGN-35) will be featured in two oral presentations at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 4-7, 2010 in Orlando, FL.

9 Nov 2010

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that data from a phase I single-agent clinical trial of brentuximab vedotin (SGN-35) will be published in the November 4, 2010 issue of the New England Journal of Medicine.

4 Nov 2010

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that brentuximab vedotin (SGN-35) will be featured in three poster presentations at the 8th International Symposium on Hodgkin Lymphoma (ISHL) being held October 23-26, 2010 in Cologne, Germany.

25 Oct 2010

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Seattle Genetics, Inc. and Millennium The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top-line results from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30. The trial was conducted in 58 relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) patients.

11 Oct 2010

Takeda announces SGN-35 ADC trial results in Hodgkin lymphoma patients

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top line results from the pivotal trial of single agent brentuximab vedotin (SGN-35), an antibody drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.

27 Sep 2010

Positive data on retreatment with brentuximab vedotin in Hodgkin lymphoma, ALCL presented at ASCO

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today reported data on Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients retreated with single-agent brentuximab vedotin (SGN-35). Preliminary data demonstrate that objective responses were achieved in seven out of 11 retreatment experiences and that brentuximab vedotin was well-tolerated in the retreatment setting.

7 Jun 2010

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.

24 May 2010

Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that data regarding retreatment experiences with brentuximab vedotin in phase I and phase II clinical trials will be presented during a poster session at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8, 2010 in Chicago, Illinois.

21 May 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2010. The company also highlighted recent product development activities and planned milestones.

28 Apr 2010

Phase III trial of brentuximab vedotin for post-transplant Hodgkin lymphoma initiated

Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited and its wholly owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of a phase III clinical trial of brentuximab vedotin (SGN-35) for post-transplant Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, which is expressed on malignant Hodgkin lymphoma cells.

8 Apr 2010

USPTO issues patent related to Seattle Genetics' ADC technology

Seattle Genetics, Inc. announced today that the U.S. Patent and Trademark Office has issued a patent related to its antibody-drug conjugate (ADC) technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics’ ADC programs, most notably brentuximab vedotin (SGN-35), as well as many ADC programs in development by its collaborators.

11 Mar 2010